GSK will acquire clinical-stage biopharmaceutical company Affinivax in a deal potentially worth over $3 billion. GSK will acquire Affinivax for an upfront payment of $2.1 billion and is offering up to $1.2 billion in potential development milestones. Affinivax is developing a novel class of vaccines, its most advanced of which is focused on pneumococcal diseases. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!